Tahoe Therapeutics – a biotech start-up based mostly in San Francisco, California – is creating the biggest ever atlas of cell-chemical interactions to tell drug discovery.
Combining automated pipetting techniques from Integra Biosciences with Parse Biosciences’ Evercode single-cell RNA sequencing (scRNA-seq) merchandise, and its personal proprietary AI algorithms, the corporate already has a number of drug discovery applications operating in parallel throughout a number of most cancers sorts, and is increasing into different therapeutic areas.
Workflow automation is important for the Tahoe Therapeutics workforce’s purpose of producing a few of the largest scRNA-seq datasets on the planet. The corporate invested in an Help Plus pipetting robotic with Viaflo handheld digital pipette to automate its analysis workflows.
Integra’s partnership with Parse Biosciences means these instruments work seamlessly with the Evercode merchandise to offer a validated, turnkey resolution masking each stage of scRNA-seq pattern preparation. These instruments allow the corporate to scale up its operations whereas enhancing reliability and decreasing hands-on time by as much as 75 %.
The corporate goals to make use of the velocity and accuracy of those automated techniques to generate a dataset fifty instances bigger than its already record-breaking Tahoe 100 million single-cell atlas.
Johnny Yu, co-founder and chief scientific officer at Tahoe Therapeutics, stated: “We rapidly realized that, as we had been producing an increasing number of information and pushing the boundaries of the sector, we had been lacking robotic and excessive throughput options.
“Automation with the ASSIST PLUS has elevated our throughput for single-cell preparation greater than 5-fold. An important factor is that it’s extremely correct: you’re not counting on the inherent variability of handbook processing.
“The mixture of INTEGRA’s devices and Parse Biosciences’ kits permits us to leapfrog many biopharmaceutical firms and generate bigger datasets utilizing much less instrumentation, reagents and capital.”
